ANZCTR search results

Hospital versus home based induction of labour This study aims to find out whether or not it is good practice to permit pregnant women to go home to rest after they have had induction of labour started. The study is important because it will identify potential advantages and disadvantages to this approach, so that women can make properly informed choices about their care.

looking at effectiveness of treating persistent cough with a medication

This study aims to determine whether intermittent treatment with the drug letrozole is more effective than continuous letrozole treatment in preventing the return of cancer in postmenopausal women with endocrine responsive breast cancer who have undergone 4 to 6 years of prior endocrine therapy. Who is it for? You may be eligible join this study if you are a postmenopausal woman who has had operable, non-inflammatory breast cancer but are now clinically disease-free. You must have completed 4 to 6 years of prior endocrine therapy with selective estrogen receptor modulators (SERM(s)), aromatase inhibitors (AI(s)), or a combination of both. Trial details Participants in this trial will be randomly (by chance) allocated to one of two groups. One group will take one 2.5mg letrozole tablet per day for 5 years. Participants in the other group will take letrozole 2.5mg tablets intermittently, i.e. once daily for the first 9 months of years 1 through 4, followed by 12 months in year 5. Participants will be regularly assessed over the duration of the trial to determine whether continuous or intermittent letrozole treatment is more effective in preventing the return of cancer and prolonging survival.

The aim of this study is to evaluate the clinical efficacy and safety of Norspan (registered trademark)(Buprenorphine Transdermal Delivery System, BTDS) in reducing neuropathic pain in patients with Postherpetic Neuralglia (PHN) compared with those on a placebo patch.

Inflammatory bowel disease (IBD) is a chronic, relapsing condition of the gastrointestinal (GI) tract. IBD is thought to result from inappropriate T cell activation due to a combination of genetic and environmental factors. This leads to a deregulated immune response and characteristic inflammation. Crohn’s disease (CD) is a form of IBD. One theory suggests that underexposure to helminths is a major environmental factor in predisposing to CD. This “hygiene hypothesis” is based on epidemiologic findings of an inverse relationship between IBD incidence and helminthic colonization. In the proposed study, the pig whipworm Trichuris suis (T. suis), formulated as ASP1002 [Trichuris suis Ova (TSO)], a suspension for oral administration, will be administered in the clinic as a single dose for 6 times. T. suis is similar morphologically to the human whipworm but is cleared too rapidly from the human host to establish infection. Therefore, it has potential for being a natural immune modulator without significant risk of causing disease in humans. The expected duration of study participation is approximately 26 to 27 weeks, including up to 2 - 3 weeks screening, a 12 week treatment period and a follow-up visit at Week 24.

Patients presenting for surgery at RMH eligible for LMA general anaesthesia

Tension-type headache (TTH) affects up to 75% of the world population and more than 33% of Australians. There is no ideal treatment for it due to the unclear mechanism. Commonly used medications include simple pain killers and anti-depressants. They are either not effective for long-term management or not tolerated by patients due to side effects. Acupuncture has been shown to reduce the frequency and intensity of TTH within three weeks of treatment and has an excellent safety profile. Cognitive behavioural therapy (CBT) teaches patients how to cope with mental stress and correct unhelpful thoughts, belief and behaviour, and thus produces a long-term effect for TTH patients. In this current trial, we aim to assess the combined effect of electroacupuncture (EA) and CBT on TTH in short and long terms. 225 TTH patients will be recruited. After a four-week run-in period and randomisation, all subjects will have one-hour interview, and then be randomly allocated to receive either EA alone, CBT alone or EA+CBT group for a total of 12-week treatment. There will be a six-month follow-up at the end of the 12 week treatment period. Subjects will record the frequency, duration, severity and symptoms of headache and the use of headache medication during run-in, the treatment and the follow-up periods. This trial will be the first such project in the world in which acupuncture is combined with a well-received and practiced intervention in pain management for TTH, i.e., CBT. The combined therapy will be cost-effective because it will reduce the consumption of analgesics and visits to doctors, and improve effectiveness at work and quality of life as a result of reduced pain and enhanced self-management skills.